NATCO Pharma Ltd. (NATCOPHARM) fundamentals
NATCO Pharma Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as NATCOPHARM (ISIN INE987B01026). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What NATCO Pharma Ltd. does
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with a focus on research and development. It develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Its segments include Pharmaceuticals and Agro chemicals. The Pharmaceuticals segment is engaged in the manufacturing and selling of bulk drugs, finished dosage formulations. The Agro Chemicals segment focuses on the manufacturing and selling of agro chemicals. It is also engaged in developing, manufacturing and marketing finished dosage formulations (FDF), active pharmaceutical ingredients (APIs) and intermediates. Its product portfolio consists of two categories of agrochemicals - pesticides and bioproducts. The key focus area is to fill the gaps in the portfolio through crop phenology analysis. It has manufacturing facilities in India which cater to both domestic and international markets.
Valuation and market data
| Last close | ₹790.20 |
|---|---|
| Market capitalisation | ₹13,688 crore |
| Enterprise value | ₹13,661 crore |
| P/E (TTM) | 9.98 |
| Price to book | 1.48 |
| Price to sales (TTM) | 1.94 |
| Book value per share | ₹532.33 |
| Dividend yield | 56.95% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Dec 27 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹3,876 crore | ₹1,364 crore | ₹1,282 crore | 71.55 |
| Mar 2025 | ₹4,416 crore | ₹2,226 crore | ₹1,850 crore | 103.31 |
| Mar 2024 | ₹3,674 crore | ₹1,555 crore | ₹1,307 crore | 72.79 |
| Mar 2023 | ₹2,437 crore | ₹771 crore | ₹637 crore | 34.90 |
| Mar 2022 | ₹1,862 crore | ₹156 crore | ₹139 crore | 7.63 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 49.4% |
|---|---|
| Foreign institutions (FII) | 16.0% |
| Mutual funds | 2.3% |
| Other domestic institutions | 3.9% |
| Retail and others | 28.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.